drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Human IgG1κ monoclonal antibody targeting CD38; induces ADCC, CDC, and apoptosis of CD38+ cells and depletes CD38+ immunosuppressive cells. Administered subcutaneously in this trial for CD38-expressing PEL/PBL and KSHV-associated MCD.
nci_thesaurus_concept_id
C74007
nci_thesaurus_preferred_term
Daratumumab
nci_thesaurus_definition
A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
drug_mesh_term
Daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Unconjugated human IgG1κ monoclonal antibody against CD38; binding to CD38 on malignant and immunosuppressive cells induces apoptosis and immune effector–mediated killing (ADCC, ADCP, CDC), depleting CD38+ tumor cells and CD38+ regulatory cells to enhance anti-tumor immunity.
drug_name
Daratumumab
nct_id_drug_ref
NCT05907759